HEMISPHERIAN AS
925333409ActiveDeveloping novel small molecule drugs targeting TET2 for aggressive cancers.
Översikt
- 5
- Anställda
- 269t NOK
- Omsättning
- 2020
- Grundat
Nyckelbeslutsfattare
Roger Stupp
Chair of the Clinical Advisory Board
Michael Lim
Member of the Clinical Advisory Board
Monika Hegi
Member of the Clinical Advisory Board
Einar O. Vik-Mo
Member of the Clinical Advisory Board
+2 fler kontakter i Funnelfeedr
Beskrivning
Hemispherian is an innovative preclinical pharmaceutical company dedicated to redefining targeted cancer therapeutics. The core focus is developing a novel class of small molecule drugs that specifically target the TET2 enzyme. These compounds are designed as targeted therapies for particularly aggr...
Taggar
Nyckelord
Företagsinformation
- Bransch
- Okänt
- Juridisk form
- Aksjeselskap
- Momsnummer
- Okänt
Beslutsfattare
6 kontakter i FunnelfeedrRoger Stupp
Chair of the Clinical Advisory Board
Michael Lim
Member of the Clinical Advisory Board
Monika Hegi
Member of the Clinical Advisory Board
Einar O. Vik-Mo
Member of the Clinical Advisory Board
Isabelle M. Germano
Member of the Clinical Advisory Board
Övriga kontakter
Josipa Matic
Medicinal Chemist (H2020 Funded)
Liknande företag
20 liknande företag i Funnelfeedr
One-carbon Therapeutics AB
Clinical-stage biotech pioneering novel anti-cancer therapies targeting metabolism.
ONCOSYNE AS
Developing cancer treatments using patient-derived 3D tumoroid models.
Double Bond Pharmaceutical AB
5–9 anställdaDeveloping advanced drug delivery systems for targeted cancer and pneumonia treatment.
OSLO SCIENCE HUB AS
Accelerating cancer treatment development through collaboration and innovation.
EXACT THERAPEUTICS AS
13 anställdaClinical-stage company developing ultrasound-mediated targeted therapy enhancement.
Utforska mer
Frågor om HEMISPHERIAN AS
Vill du se Funnelfeedr i praktiken?
Boka en gratis demo och upptäck hur Funnelfeedr hjälper dig att hitta och konvertera dina idealkunder.
Boka en demo